TIDMMEDG TIDMMEDU
RNS Number : 0656I
Medgenics Inc
08 June 2011
Medgenics, Inc.
('Medgenics' or the 'Company')
Block Listing interim review
8 June 2011
1. Name of company:
Medgenics, Inc.
2. Name of scheme:
Warrants and Options under the Company's Share Incentive
Schemes
3. Period of return: From To
4 December 2010 3 June 2011
4. Number and class of securities not issued under the scheme at
the beginning of the period:
170,501 common shares of par value of US$0.000 1 each ("Common
Shares")
5. Number of securities issued under scheme during period:
170,501 Common Shares following the due exercise of Warrants and
Options issued by the Company
6. Balance under scheme of securities not yet issued at end of
period:
0 Common Shares
7. Number and class of securities originally admitted and the
date of admission:
594,820 Common Shares admitted under the block admission on 4
December 2007.
For further information, contact:
Andrew Pearlman +972 4 902 8900
CEO
Medgenics, Inc
Mike Wort / Anna Dunphy +44 207 556 1064
De Facto Finance (IR)
James Pinner / Derek Crowhurst +44 207 444 0800
Religare Capital Markets (NOMAD)
Ian Callaway / Alex Mattey +44 207 638 5600
SVS Securities plc (Joint Broker)
Jonathan Senior +44 207 776 1219
Nomura Code (Joint Broker)
Anne Marie Fields
Lippert/Heilshorn & Associates,
Inc. +1 212-838-3777
---------------------------------- ----------------
Notes to Editors:
Medgenics is developing and commercializing Biopump, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases
including anemia, hepatitis C and hemophilia. Medgenics believes
this approach has multiple benefits compared with current
treatments, which include regular and costly injections of
therapeutic proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
-- EPODURE (now completing a Phase I/II dose-ranging trial) to
produce and deliver erythropoietin for many months from a single
administration, has demonstrated elevation and stabilization of
hemoglobin levels in anemic patients for 6 to more than 24
months;
-- INFRADURE (to commence a Phase I/II trial in Israel in 2011)
to produce a sustained therapeutic dose of interferon-alpha for use
in the treatment hepatitis C;
-- HEMODURE is a sustained Factor VIII therapy for the
prophylactic treatment of hemophilia, now in development.
Medgenics intends to develop its innovative products and bring
them to market via strategic partnerships with major pharmaceutical
and/or medical device companies. Since October 2009, HEMODURE has
been the focus of cooperation between Medgenics and a major
healthcare company, a market leader in hemophilia.
In addition to treatments for anemia, hepatitis C and
hemophilia, Medgenics plans to develop and/or out-license a
pipeline of future Biopump products targeting the large and rapidly
growing global protein therapy market, which is forecast to reach
$132 billion in 2013. Other potential applications for Biopumps
include multiple sclerosis, arthritis, pediatric growth hormone
deficiency, obesity and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will, " "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRFPMPTMBBMMJB
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024